Oct 20 (Reuters) – The US FDA said on Tuesday it had approved British drugmaker GSK’s hepatitis B drug Hibsago, offering patients with the liver infection a way to keep the virus under control after stopping treatment.
The drug, chemically known as bepirovirsen, is the first FDA-approved antisense oligonucleotide for chronic hepatitis B, according to the agency.
(Reporting by Padmanabhan Ananthan in Bengaluru and Bhanvi Satija in London; Editing by Diti Pujara)
Brought to you by www.srnnews.com
